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ABSTRACT
Background: Genetic alterations on chromosome 9p, including inactivation of the 
tumour suppressor gene, CDKN2A, result in cellular proliferation and growth of tumours. 
Our aim was to use microsatellite analysis and fluorescence in situ hybridization (FISH) 
to characterise the architecture of this region. 
Results: Seventy-five out of 77 clear cell renal cell cancers (tumour/normal pairs) 
were interpretable for LOH analysis on chromosome 9p (two tumours were excluded, 
as all five primers were uninformative). Twenty out of 75 (26.6%) tumours showed 
LOH in at least one of the five primers employed. Most allelic deletions were detected, 
telomeric to the CDKN2A region at D9S916, with 11 out of 52 informative tumours 
(21%) displaying LOH. The LOH in the coding region of CDKN2A, at D9S974 and 
D9S942, was associated with a higher pT-stage (p = 0.004) and metastasis (p = 0.006, 
both markers). The rate of chromosome 9p deletion in ccRCC was 44% (35/80 cases) 
according to FISH. Somatic copy number loss of chromosome 9p was associated with a 
larger tumour size (p = 0.002), higher pathological tumour stage (p = 0.021), presence 
of tumour necrosis (p = 0.019) and microvascular invasion (p = 0.032). The cases with 
copy number loss, loss of heterozygosity and copy number neutral (n = 42) were at a 
higher risk of cancer-specific death when compared to tumours in category D (n = 32) 
(Log-rank: p = 0.001). Seventeen patients with localised ccRCC developed recurrence, 
and fourteen of those showed either LOH or somatic copy number loss at CDKN2A 
(Log-rank: p = 0.005). Multivariate analysis showed that LOH or copy number loss at 
CDKN2A retained its independent prognostic effect, improving the predictive accuracy 
of stage and SSIGN score by concordance Index C from 0.823 to 0.878 (p = 0.001).
Materials and Methods: Cytogenetics data, microsatellite analysis and FISH 
were acquired for a cohort of patients undergoing resection for clinically localised 
renal cancer between January 2001 and December 2005. Five microsatellite markers 
(D9S916, D9S1814, D9S974, D9S942 and D9S171) assessed loss of heterogeneity 
(LOH) using DNA samples and in the same cohort FISH analysis was accomplished 
on tissue microarray slides. The FISH data were scored by two observers blinded to 
the histological data of the patients. Cytogenetic aberrations were correlated with 
histological and clinical outcomes by univariate and multivariate analyses using 
different prognostic models. Disease specific and recurrence free survival based on 
cytogenetic changes were assessed by Kaplan Meier methods. 
Conclusions: A comprehensive cytogenetic analysis using microsatellite analysis 
and FISH of the CDKN2A region on chromosome 9p improves the predictive accuracy 
of known prognostic factors in clinically localised renal cell carcinoma undergoing 
surgical resection.
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INTRODUCTION
Loss of heterozygosity (LOH) and copy number 
deletion are two different cytogenetic aberrations which 
can result in down-regulation or inactivation of a gene. 
These two mechanisms could be involved in tumour 
progression if they result in inactivation of tumour 
suppressor genes, such as CDKN2A/B located on 
chromosome 9p.
CDKNA region contains genetic information for 
the synthesis of many tumour suppressor proteins such 
as p16 INK4a, p14ARF, and p15INK4b. These proteins regulate 
progression of cellular proliferation through cell cycle, 
for example p16INK4a plays a key role in transition of 
cell from G1-S phase in the cell cycle through p16-Rb 
pathway. In addition, this plays an active role in cellular 
senescence, p16 through interconnections influences 
tumor suppressor P53 pathways [1, 2] Any alteration in 
this region (mutation or hypermethylation) can potentially 
lead to reduced or no synthesis of these proteins and hence 
unregulated growth of cells [3]. 
Several cytogenetic methods, such as fluorescence 
in situ hybridization (FISH), comparative genomic 
hybridization (CGH) and microsatellite analysis, have 
been reported; each has its advantages and disadvantages. 
A recent review of published literature on prognostic value 
of 9p deletion in RCC has shown that most studies were 
observational and used a wide variety of molecular and 
conventional cytogenetic techniques. The studies were 
mostly old series with no common protocols, which led 
to a discrepancy in the outcomes and the quality of the 
studies reviewed [4]. 
Three studies have shown that somatic copy number 
loss involving 9p can be associated independently with 
worse outcomes in ccRCC. All three studies relied on 
I-FISH to assess loss of chromosome 9p; however, the 
criteria and cut-off values used to define deletion differed 
among the studies, as did the probes employed [5–7]. Our 
group used I-FISH to carry out a validation study and 
confirmed the above findings in patients with surgically 
resected RCC that had the longest follow-up [8]. The 
probe employed was a dual-colour probe with a locus-
specific identifier on the CDKN2A gene.
By contrast, studies using microsatellite analysis 
have demonstrated that LOH on chromosome 9p is 
associated with adverse histological features and a risk 
of progression of renal cancer [9–11]. Microsatellite 
analysis, using paired control normal renal tissue and 
tumour DNA, is a sensitive technique for detecting LOH 
in tumours. It is a fast and inexpensive analytical method 
and can be performed on degraded DNA extracted from 
formalin-fixed, paraffin-embedded tissue. Kinoshita et al. 
were the first to propose that LOH in the region of 9p21 
was associated with progression of RCC and metastasis 
[9], but the study lacked long-term follow-up. Only a few 
studies correlated the allelic deletion of 9p and survival 
with varied follow-up duration which ranged between 31 
and 48 months [11–13]. Some studies relied on only one 
or two microsatellites telomeric to 9p21 for assessment of 
allelic deletion of 9p and could therefore have missed more 
centromeric LOH involving regions harbouring several 
tumour suppressor genes involved in cell cycle regulation. 
In comparison to I-FISH, microsatellite karyotyping 
detects LOH in the absence of copy number variation 
(deletion). This phenomenon is also known as copy 
number neutral LOH (CNNLOH) and was previously 
called uniparental disomy (UPD). Studies on oesophageal 
cancer have shown that copy number neutral LOH is a 
common phenomenon [14, 15] The literature contains 
few reports on CNN-LOH in clear cell RCC especially 
in the region of chromosome 9p21, which harbours 
CDKN2A/B, one of the main tumour suppressor genes. 
CNN-LOH could therefore be an underestimated event 
which could result in gene inactivation due to duplication 
of the mutated or non-functioning allele. 
The objective of the present study were: 
(i)  to assess the concordance between microsatellites 
and I-FISH, including the diagnostic utility of the 
individual methods.
(ii)  to determine whether the overall prognostic impact 
of a 9p deletion could be improved using a strategy 
incorporating FISH and LOH analysis, particularly in 
conjunction with long-term follow-up. 
RESULTS
Cohort characteristics
The study population included 89 (82.4%) patients 
with clear cell histology, 13 (12%) with papillary renal 
cell carcinoma (pRCC), 5 (4.6%) with chromophobe 
appearance and one (1%) with collecting duct 
carcinoma. The clear cell subtype was the focus of this 
study; therefore, somatic copy number loss and LOH 
in the 9p region were analysed in relation to adverse 
histopathological factors and survival only in this subtype. 
However, we included all the subtypes in the concordance 
analysis of LOH between microsatellites and I-FISH. 
The mean age of patients with ccRCC was 62.8 (range 
38–84) with a mean follow-up of 80 months (range 6–165 
months). 
Microsatellite analysis of LOH at the 9p21 region 
and correlation with pathological parameters in 
ccRCC
In total, 96 out of 108 cases represented on the tissue 
microarrays (TMAs) were tested for LOH with 5 markers. 
Four markers (D9S916, D9S974, D9S942 and D9S1814) 
were within the 9p21 region and 1 marker (D9S171) 
was within 9p13 region. Seventy-seven (80%) tumours 
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were clear cell subtype, 13 (13.5%) were papillary RCC, 
5 (5.2%) were chromophobe RCC, and only one was 
collecting duct RCC.
Except for two uninformative cases, 75 out of 77 
ccRCC tumour/normal pairs were interpretable for LOH 
analysis on chromosome 9p (Figure 1). Average tumour 
size for these patient was 6.3 cm. The mean age in this 
cohort was 62.5 years old. The median follow-up was 
91.8 months (mean 85 months). Again, details of allelic 
deletions have been reported previously [16]. 
In addition to previous publication, LOH at D9S916 
was statistically associated with a higher pT stage 
(p = 0.005), sarcomatoid changes (p = 0.026), and renal 
sinus invasion (p = 0.014), with only an observed trend for 
metastasis (p = 0.10).
The LOH within the coding region of CDKN2A, at 
D9S974 and D9S942, was also associated with higher pT 
stage (p = 0.004 and p = 0.003, respectively and metastasis 
(p = 0.006, both markers). The LOH within D9S974 and 
D9S942 was also associated with renal sinus invasion 
(p = 0.015 and p = 0.006, respectively. 
Almost half the cases were uninformative at 
D9S1814, but the LOH at this locus was associated 
only with higher pT stage (p = 0.028). A trend was also 
observed with renal sinus invasion (p = 0.059).
On the other hand, LOH was the only marker within 
9p13 (D9S171) and showed a correlation with renal sinus 
invasion only (p = 0.027). A trend was also noted with 
pathological tumour stage (p = 0.083).
Fluorescence in-situ hybridisation and 
correlation with pathological parameters
Of the 108 tumours, 98 had valid 9p scoring on the 
TMA. Eighty of these 98 cases were ccRCC subtype and 
were included in the survival analysis in this study. Twelve 
were papillary RCC, five were chromophobe RCC and 
only one was a collecting duct carcinoma. 
A complete description of the results of this 
experiment was previously reported [8, 7]. Based on I-FISH 
interpretation using pre-set criteria, the rate of chromosome 
9p deletion in ccRCC was 44% (35/80 cases). Somatic copy 
number loss of chromosome 9p was associated with a larger 
tumour size (p = 0.002), a higher pathological tumour stage 
(p = 0.021), the presence of tumour necrosis (p = 0.019) and 
microvascular invasion (p = 0.032). 
Concordance between LOH on microsatellite 
analysis and fluorescence in-situ hybridization in 
all RCC specimens
Ninety-six cases (paired tumour and normal tissue) 
were assessed for microsatellite analysis and included in 
the concordance analysis for 9p loss using FISH. 
Of the 68 cases with informative markers within the 
coding region of CDKN2A (D9S974 and D9S942), LOH 
was observed in 17 tumours (25.7%), with 7 tumours 
showing LOH at both microsatellites and 10 tumours 
showing LOH for one of the two markers. 
Figure 1: Microsatellite analysis is showing allelic deletion in tumour 81 involving more than one marker.
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Sixty-three of the 68 informative cases had valid 
I-FISH scores available for comparison. Four tumours 
were excluded from concordance analysis as they were 
marked as a homozygous loss by I-FISH. In total, 59 
tumours were available for concordance analysis between 
microsatellites and I-FISH. Both techniques agreed on 
30 tumours showing no LOH or copy number loss at 
CDKN2A. LOH within CDKN2A region was detected and 
agreed upon by both the techniques in 6 tumours. Overall, 
the concordance rate between microsatellites and I-FISH 
was 61% (36/59).
On the other hand, microsatellite analysis showed 
LOH at CDKN2A in 9 tumours that did not show copy 
number loss on FISH. This finding could be explained 
by the common phenomenon of copy number neutral 
LOH (CNNLOH). The rate of CNNLOH at the CDKN2A 
coding region was 60% (9/15).
A further analysis of 14 tumours showing 9p loss 
using I-FISH, with an average pooled percentage of 
abnormal nuclei of 49% (range: 39–60%), did not show 
allelic loss on microsatellite analysis. As a result, the 
sensitivity of microsatellite analysis to detect copy number 
loss LOH was poor (30%; 6/20) when compared to FISH. 
Combined copy number loss and loss of 
heterozygosity on chromosome 9p and its impact 
on prognosis in ccRCC
The data of copy number loss using FISH and from 
microsatellite analysis on the LOH in the CDKN2A region 
were combined to assess the impact of aberrations on the 
outcomes of ccRCC. Seventy-four tumours with complete 
information were divided into four categories: 
A. Tumours with somatic copy number loss (n = 29).
B.  Tumours with somatic copy number loss and LOH 
(n = 6).
C. Tumours with copy number neutral LOH (n = 7).
D.  Tumours with normal copy number and heterozygous 
(n = 32).
The cases in the first three groups combined (n = 42) were 
at a higher risk of cancer-specific death when compared 
to tumours in category D (n = 32) (Figure 2: Log-rank: 
p = 0.001). Seventeen patients with localised ccRCC 
developed recurrence; fourteen of these showed either 
LOH or somatic copy number loss at CDKN2A (Figure 3: 
Log-rank: p = 0.005). 
Univariate Cox-proportional hazard analysis 
revealed that cases with LOH or copy number loss at 
CDKN2A showed a higher hazard ratio when compared 
to each aberration independently for disease-specific 
survival (DSS) and recurrence-free survival (RFS) 
(Table 1). All cases were categorised based on LOH status 
and copy number loss at CDKN2A in relation to validated 
prognostic nomograms for metastasis or RFS and DSS in 
ccRCC (Table 2). 
Multivariate analysis for DSS revealed that LOH or 
copy number loss at CDKN2A retained its independent 
prognostic effect with pathological T stage and state of 
metastasis in model 1 (Table 3). It also remained as an 
independent prognostic factor with the Mayo Clinical 
Stage, Size, Grade and Necrosis (SSIGN) score in 
model 2, improving its predictive accuracy expressed by 
concordance Index C from 0.823 to 0.878 (p = 0.001).
On the other hand, multivariate analysis for RFS 
showed that combination of copy number loss or LOH 
at CDKN2A is an independent prognostic factor for 
recurrence in ccRCC in addition to the pT stage in model 3 
(Table 4). The integration of copy number loss or LOH at 
CDKN2A with the Leibovich score enhanced its predictive 
accuracy expressed by concordance Index C from 0.734 to 
0.801 (p = 0.009).
DISCUSSION
This study has confirmed previous findings 
where the LOH on chromosome 9p in clear cell RCC is 
associated with adverse histopathological features and 
worse prognosis, but it also showed enhanced prognostic 
significance when LOH is combined with FISH analysis. 
The detection rate of allelic deletion-as previously 
reported- on chromosome 9p in ccRCC by [16] studies 
using microsatellites [10, 12, 13] and more contemporary 
studies relying on SNP arrays [21, 22]. 
The LOH within the coding region of CDKN2A 
was associated with higher tumour grade and a higher risk 
of metastasis. The frequency of LOH for all 4 markers 
on 9p21 (D9S916, D9S974, D9S942 and D9S1814) was 
significantly associated with locally advanced tumours, 
highlighting our previous observation that LOH could be 
a biomarker for aggressive renal cell cancer. The LOH 
on 9p21, especially the markers within the region of 
CDKN2A in addition to D9S916, were all independent 
prognostic factors in multivariate analysis models when 
Table 1: Concordance between FISH and microsatellite analyses in the region of CDKN2A
Concordance
Analysis
I-FISH
No Deletion Monosomy/LOH Total
LOH analysis with 
microsatellites
No 30 14 44
Yes 9 6 15
Total 39 20 59
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integrated separately for DSS. In the group of clinically 
localised ccRCC, the LOH in the CDKN2A region was 
associated with a higher risk of recurrence or development 
of metastatic disease, as determined by univariate analysis 
(p = 0.023; HR 4.04).This LOH remained an independent 
prognostic factor in the multivariate analysis model 
including the Leibovich score (p = 0.014; HR = 4.7). 
These findings confirm again that LOH involving 
chromosome 9p21, and particularly LOH at the coding 
region of CDKN2A, portends a worse prognosis in ccRCC 
in long term follow up and they validated the findings 
from I-FISH-based analysis of 9p deletion. 
Previous studies have suggested that the LOH on 
chromosome 9p is associated with adverse histological 
Table 2: Univariate Cox proportional hazard model
Univariate analysis for disease-specific survival (DSS)
Variable Categories p-value Hazard Ratio
95% CI
Lower Upper
LOH at CDKN2A Yes vs. No 0.005 5.374 1.644 17.564
Somatic deletion at 
CDKN2A Yes vs. No 0.002 5.703 1.904 17.077
Combined deletion or 
LOH at CDKN2A
Deletion or LOH vs. 
normal 0.004 8.464 1.958 36.578
Univariate analysis for recurrence-free survival (RFS)
Variable Categories p-value Hazard Ratio
95% CI
Lower Upper
LOH at CDKN2A Yes vs. No 0.023 4.040 1.213 13.460
Somatic deletion at 
CDKN2A Yes vs. No 0.003 5.365 1.763 16.327
Combined deletion or 
LOH at CDKN2A
Deletion or LOH vs. 
normal 0.007 5.620 1.670 32.674
Figure 2: Kaplan Meir analysis clearly showing poor disease specific survival in patients with cytogenetic abnormalities 
on chromosome 9p.
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features and risk of progression of renal cancer [11, 9, 10]. 
Kinoshita et al. were the first to propose that LOH in the 
region of 9p21 was associated with progression of RCC 
and metastasis [9], but the study lacked long-term follow-
up. Our literature search revealed several studies that 
reported on allelic deletion on chromosome 9p in renal 
cancer, but only a few studies established correlations 
between allelic deletion of 9p and survival with sufficient 
follow-up periods [11, 13]. Some of the studies relied on 
only one or 2 microsatellites telomeric to 9p21 to assess 
allelic deletion of 9p, which could have missed more 
centromeric LOH involving regions harbouring several 
tumour suppressor genes involved in cell cycle regulation. 
Allelic deletion of 9p was assessed by 5 markers covering 
the 9p21 region, as the region of interest that harbours 
CDKN2A/B genes, and to validate I-FISH results, 
which relied on a dual-colour probe with a locus-specific 
identifier on CDKN2A.
The follow-up period in the previous studies ranged 
between 31 and 48 months (median), compared to 91 
months median follow-up in this study. The extended 
follow-up period for this cohort allowed assessment of the 
impact of LOH on 9p21, and especially the coding region 
of CDKN2A, on survival. The prognostic impact of LOH 
Table 3: Association between copy number loss and LOH on CDKN2A with SSIGN and Leibovich 
scores
Copy number loss at 
CDKN2A
LOH at 
CDKN2A
LOH or copy number loss at 
CDKN2A
Deletion No deletion LOH Normal Yes No
SSIGN score
Low (0–3) 10 25 5 28 13 19
Intermediate (4–7) 15 13 5 18 17 8
High (8–13) 10 7 3 8 12 5
Total 35 45 13 54 42 32
Leibovich 
score
Low (0–2) 5 20 2 21 7 16
Intermediate (3–5) 12 13 6 17 15 8
High (6–11) 12 8 2 13 12 6
Total 29 41 10 51 34 30
Figure 3: Showing better recurrence free survival in patients with no loss of heterozygosity or deletion of chromosome 9p.
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on 9p was determined by integrating it within multivariate 
models including the most significant variables and in 
externally validated prognostic models for cancer-specific 
survival and metastasis-free survival. 
Microsatellite analysis has the advantage of 
detecting loss of heterozygosity in the absence of copy 
number variation (deletion), which is also known as 
copy number neutral LOH (CNNLOH). Studies on 
several cancers have shown that CNNLOH is a common 
phenomenon, but its correlation with gene expression 
remains poorly understood. It could still be considered to 
represent a mechanism of gene inactivation, especially if 
the wild type allele is lost and the non-functioning one is 
duplicated to maintain a copy neutral status [14, 15].
The incidence of CNNLOH has been studied in 
detail in oesophageal cancer, and it appeared to play a 
role in carcinogenesis and was associated with a change 
in gene expression levels, either by up-regulation or 
down- regulation. However, the authors concluded that 
the mechanism remains poorly understood [14, 15]. The 
authors suggested that CNNLOH was more common than 
LOH with copy number alteration in oesophageal cancer 
and represented 70% of all allelic deletions detected by 
single nucleotide polymorphism (SNP) arrays. Saeki et al. 
reported copy neutral LOH of the p53 locus in p53 mutant 
oesophageal cancer and suggested that this could be a major 
mechanism for inactivation of the intact allele in oesophageal 
squamous cell carcinogenesis associated with a mutation at 
p53. The authors suggested five scenarios that could result in 
LOH on p53; three of them are copy neutral [15]. 
The present study revealed CNNLOH in 9 tumours. 
As expected, these were not detected by I-FISH alone and 
hence alternate/complementary techniques are required 
to map these areas. On the contrary, copy number loss on 
chromosome 9p was detected by I-FISH alone but not by 
microsatellite analysis. This discordance can be explained by 
a number of factors; for example, contamination of tumour 
samples during macro-dissection (viable tumour areas were 
marked by a specialist pathologist on tumour blocks in this 
study); intratumour heterogeneity causing contamination of 
DNA predominantly from a sub clone with no copy number 
loss; or a high percentage of homozygous loss or DNA 
Table 4: Multivariate Cox proportional hazard model analysis for RFS and DSS
Model 1 for RCC disease-specific survival (DSS)
Variable Categories p-value Hazard Ratio
95% CI
Lower Upper
Combined deletion or LOH at 
CDKN2A 
Deletion or LOH vs. 
normal 0.045 4.568 1.031 20.238
T-stage pT3/4 vs. pT1/2 0.006 6.724 1.710 26.435
Metastasis N+M+ vs. N0M0 0.003 4.532 1.678 12.241
Model 2 for RCC disease-specific survival (DSS)
Variable Categories p-value Hazard Ratio
95% CI
Lower Upper
Combined deletion or LOH at 
CDKN2A 
Deletion or LOH vs. 
normal 0.010 6.808 1.567 29.567
SSIGN score 3 sub-categories < 0.001 4.361 2.163 8.974
Model 3 for recurrence-free survival (RFS)
Variable Categories p-value Hazard Ratio
95% CI
Lower Upper
T-stage pT3/4 vs. pT1/2 0.007 4.188 1.491 11.761
Combined deletion or LOH at 
CDKN2A 
Deletion or LOH vs. 
normal 0.023 5.701 1.265 25.701
Model 4 for recurrence-free survival (RFS)
Variable Categories p-value Hazard Ratio
95% CI
Lower Upper
Combined deletion or LOH at 
CDKN2A 
Deletion or LOH vs. 
normal 0.019 5.968 1.347 26.435
Leibovich score 3 sub-categories 0.006 3.061 1.387 6.758
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sample contamination with normal renal tissue. The lack of 
sensitivity of microsatellite analysis in reference to FISH to 
detect copy number loss LOH comes down predominantly 
to the superiority of FISH to cut through tumour complexity 
at a cellular level, allowing the observer to score regions of 
tumour in more than one core that has a high concentration 
of cells with copy number loss. This advantage is clearly 
lost in microsatellite analysis as it relies on DNA extracted 
from a macro-dissected tumour region, resulting in dilution 
of abnormality by a mixture of normal cells and tumour cells 
without copy number loss of chromosome 9p. Previous work 
has shown that if the proportion of tumour cells in a sample 
diminishes to 50% or less, the ability to detect the LOH is 
reduced [23]. Moreover, the discordance could have been 
the result of sampling bias; I-FISH results were based on 
the scoring of 6 different cores in contrast to three 8–10 µm 
curls used for DNA extraction for microsatellite analysis. The 
increase in the number of sampled tumour regions clearly 
improves the detection and identification of more subclones 
[24]. This could have been potentially prevented by laser 
microdissection of tumour tissue before DNA extraction to 
avoid contamination with normal renal tissue or necrotic 
tumour tissue, which is a potential limitation in our study. 
The addition of copy number status to allelic 
deletion measured by LOH analysis at the CDKN2A 
coding region on chromosome 9p significantly enhances 
the predictive accuracy of the SSIGN score and Leibovich 
score for cancer-specific death and development of 
metastasis in patients undergoing resection for clinically 
localised renal cell carcinoma. The assessment of copy 
number loss with I-FISH and LOH using microsatellites 
is complementary for the detection of copy number 
aberrations and provides better prognostication data. 
However, discordance still exists in a number of cases for 
reasons explained in this study. 
In conclusion, combined cytogenetic techniques 
improve the prognostic significance of known factors 
in clinically localised renal cancer following surgery. 
Copy number neutral LOH, seen in 10% of the cohort, 
carries a worse prognosis and perhaps could be a potential 
candidate for closer follow-up or adjuvant therapy. 
MATERIALS AND METHODS
Study cohort
The database of Tayside Urological Cancer Network 
(TUCAN) databases were searched for consecutive 
patients who underwent radical nephrectomy for Renal 
Cell Carcinoma (RCC) between Jan. 2001 and Dec. 
2005. This allowed each participants of the study to 
have atleast 10 years of follow-up. This is same cohort 
described previously in detail for Fluorescent in situ 
hybridization and microsatellite alteration studies [8, 16]. 
Ethical approval through local research committee (Ref. 
12/ES/0083) was obtained prior to initiation of the study. 
Patients were followed up using a standard protocol based 
on tumour stage and grade. All tumour characteristics, 
clinical and follow-up data were collated for each case. 
Tumours were examined and re-classified according to 
the 2009 TNM staging [17–19]. All cases were assigned 
a Mayo-Clinic SSIGN score [17] and only cases with 
localized ccRCC were assigned a Leibovich score [20].
Follow-up was calculated from the time of surgery 
to the last date of assessment or date of death. The cause 
of death was determined based on death certificates and 
correspondence between clinicians and patients’ general 
practitioners. Death from renal cancer was defined as 
disease-related mortality. Recurrence was diagnosed if 
RCC metastasis or renal bed recurrence was detected 
on cross-sectional imaging and confirmed in a multi-
disciplinary team meeting record.
Tissue microarray (TMA)
This was described in previous publication from 
the same institution [7, 19]. In summary, TMAs were 
constructed using Beecher® arraying instrument (Beecher 
Instruments Inc., Sun Prairie, WI, USA) with the help of 
TMA Designer® 2 software. Tissue cores with a diameter 
of 0.6 mm were punched from the marked tumour regions 
on paraffin blocks after being marked by the pathologist. 
Cores were then deposited into a master paraffin block and 
placed 1.2 mm apart from the neighbouring core on the 
x and y-axes. Sections from the resulting master paraffin 
block measuring 4 µm in thickness were then transferred 
onto glass slides to form a TMA. Each case was represented 
at least with six tumour cores. A TMA from normal renal 
tissue from the same cases was constructed to be used as a 
control to determine the cut-off threshold for deletion.
Fluorescence in-situ hybridization (FISH)
Interphase I-FISH analysis was performed using 
the Vysis Locus-Specific Identifier (LSI) CDKN2A 
spectrum red (R)/(CEP 9) spectrum green (G) probes 
(Abbott Molecular, USA). The process of applying the 
probe to TMA slides is described in detail in our previous 
publication. Interpretation of I-FISH, using pre-set criteria, 
was carried out by 2 independent observers blinded to 
clinical outcomes to determine 9p status in each tumour 
based on 6 representative cores on the TMA and relying on 
control normal tissue to set threshold for deletion. Any dis-
agreement was settled by reviewing slides and consensus. 
An algorithm describing the interpretation of I-FISH for 
9p deletion was published previously [8]. 
DNA extraction from formalin-fixed  
paraffin-embedded tissue samples
Three curls were cut from the same FFPE tumour 
blocks that were represented by six cores on the tumour 
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TMAs. This was done to minimise the risk of sampling 
bias and reduce the effect of intratumour heterogeneity on 
the results. 
DNA extraction was undertaken from FFPE tumour 
curls and corresponding normal tissue curls from the same 
patient using the automated EZ1 BioRobot method. This 
extraction protocol relies on the use of magnetic particles 
that bind to the DNA and are subsequently removed from 
the surrounding tissue by a separate magnetic source. As 
with the manual methods, 180 µl ATL tissue lysis buffer 
was added to each sample (2 × 10 µM FFPE sections) 
together with 20 µl Proteinase K solution. The samples 
were placed in an Eppendorf Thermomixer and incubated 
at 56°C with vigorous shaking for one hour. At the end of 
this period, the thermomixer temperature was increased 
to 90°C and incubated another hour, again with vigorous 
shaking. The samples were then loaded into a cartridge 
and placed in the EZ1 Robot. All the reagents required 
for the extraction of DNA from a sample are present in a 
single cartridge. An elution volume of 50 µl ATE buffer 
was used before DNA sample was stored at –20°C until 
use. All DNA samples concentration and quality were 
assessed by NanoDrop 1000 spectrometer (Thermo Fisher 
Scientific,Wilmington, Del).
Microsatellites markers 
Five fluorescent end-labelled microsatellite markers 
that map to the 9p13–21 region were used after being 
checked for possible single nucleotide polymorphisms 
(SNP). Four markers map to 9p21; D9S916, D9S1814, 
D9S974 and D9S942. The latter two are within the coding 
sequence of CDKN2A. D9S916 is telomeric to CDKN2A 
and CDKN2B, whereas D9S1814 is centromeric to 
CDKN2B. D9S171 is at 9p13 (proximal toCDKN2A/B). 
The details of these microsatellite markers have been 
described in our recent study [16].
PCR amplifications were performed in a final 
volume of 24ul and consisted of 10X PCR reaction buffer, 
2 mM dNTPs, forward and reverse primers, HotStarTaq 
DNA Polymerase® (Qiagen®) and distilled H2O. All PCRs 
reagents were mixed in one tube, 24 µl of the reaction 
mix was aliquoted into each tube pre-labelled with the 
sample number. The sample DNA was added (usually 1 µl; 
50–200 ng) to each corresponding labelled tube and tubes 
placed in the thermal cycler. 
The PCR programme employed consisted of 1 cycle 
at 95°C for 15 minutes for activation of HotStarTaq. This 
was followed by 35 cycles of denaturation step (94°C for 
40 seconds), then annealing step (55°C for 40 seconds), 
followed by elongation or extension step (72°C for 40 
second). Finally the programme terminates with 1 cycle 
of cooling (8°C for 7 minutes, then 4°C for 1 minute) 
Following amplification, 0.5 µl of the product was 
denatured in deionized formamide and the fluorescent 
markers analysed by capillary electrophoresis. Determination 
of loss of heterozygosity (LOH) status was carried out by 
staff in the NHS Genetic Laboratory, using GeneMarker® 
Software V2.4.0 (SoftGenetic®, State College, PA 16803, 
USA). For informative cases, the allelic loss was scored if 
the signal intensity of one allele was reduced by more than 
40% in the tumour DNA compared to the corresponding 
allele in normal DNA.
Statistical analysis
The clinicopathological data were compared based 
on 9p status. Proportions between categorical variables 
were compared using Fisher’s exact and Pearson chi-
square tests, as appropriate. The survival time was 
summarised using mean and ranges. Other continuous 
variables were summarised as means and standard 
deviation (SD) and compared using Student-t tests or 
Mann-Whitney U test as appropriate. 
The Kaplan-Meier method was used to estimate 
RFS and DSS based on 9p status and other variables. The 
log-rank test was used to compare the survival differences 
between the groups.
A univariate Cox proportional hazard model was 
used to assess the correlation between prognostic variables 
and recurrence, and RCC-specific mortality. Multivariate 
analysis was performed for DSS and RFS after excluding 
the insignificant variables in univariate analysis. Backwards 
selection manner with the likelihood ratio criterion (for 
entry and removal: p ≤ 0.05 and p > 0.1 respectively) and 
rank of elimination was used to identify the most significant 
variables to be entered in the final models for RFS and 
DSS. The predictive accuracy of prognostic models was 
assessed by employing Concordance index (C-index). 
Statistical analysis was performed using IBM® SPSS® 
– version 21, with all tests being two-tailed and p < 0.05 
considered statistically significant.
CONFLICTS OF INTEREST 
None.
REFERENCES
 1. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and 
tumor suppressor gene p16. International journal of cancer. 
2012; 130:1715–1725.
 2. Harris SL, Levine AJ. The p53 pathway. positive and 
negative feedback loops. Oncogene. 2005; 24:2899–2908.
 3. Nichols AC, Yoo J, Palma DA, Fung K, Franklin JH, 
Koropatnick J, Mymryk JS, Batada NN, Barrett JW. 
Frequent mutations in TP53 and CDKN2A found by next-
generation sequencing of head and neck cancer cell lines. 
Archives of otolaryngology—head & neck surgery. 2012; 
138:732–739.
 4. El-Mokadem I, Fitzpatrick J, Rai B, Cunningham J, Pratt N, 
Fleming S, Nabi G. Significance of chromosome 9p status 
in renal cell carcinoma: a systematic review and quality of 
Oncotarget10www.impactjournals.com/oncotarget
the reported studies. BioMed research international. 2014; 
2014:521380.
 5. Brunelli M, Eccher A, Gobbo S, Ficarra V, Novara G, 
Cossu-Rocca P, Bonetti F, Menestrina F, Cheng L, Eble JN, 
et al. Loss of chromosome 9p is an independent prognostic 
factor in patients with clear cell renal cell carcinoma. 
Modern pathology. 2008; 21:1–6.
 6. La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, 
Said J, Shuch B, Zomorodian N, Kabbinavar F, 
Belldegrun A, et al. Chromosome 9p deletions identify an 
aggressive phenotype of clear cell renal cell carcinoma. 
Cancer. 2010; 116:4696–4702.
7. de Oliveira D, Dall'Oglio MF, Reis ST, Zerati M, Souza IC, 
Leite KR, Srougi M. Chromosome 9p deletions are an 
independent predictor of tumor progression following 
nephrectomy in patients with localized clear cell renal cell 
carcinoma. Urologic oncology. 2014; 32:601–606.
 8. El-Mokadem I, Fitzpatrick J, Bondad J, Rauchhaus P, 
Cunningham J, Pratt N, Fleming S, Nabi G; Chromosome 
9p deletion in clear cell renal cell carcinoma predicts 
recurrence and survival following surgery. British journal 
of cancer. 2014; 111:1381–1390.
 9. Kinoshita H, Yamada H, Ogawa O, Kakehi Y, Osaka M, 
Nakamura E, Mishina M, Habuchi T, Takahashi R, 
Sugiyama T, et al. Contribution of chromosome 9p21-22 
deletion to the progression of human renal cell carcinoma. 
Japanese journal of cancer research. 1995; 86:795–799.
10. Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. 
Loss of heterozygosity at chromosomes 8p, 9p, and 14q is 
associated with stage and grade of non-papillary renal cell 
carcinomas. The Journal of pathology. 1997; 183:151–155.
11. Li X, Tan X, Yu Y, Chen H, Chang W, Hou J, Xu D, Ma L, 
Cao G. D9S168 microsatellite alteration predicts a poor 
prognosis in patients with clear cell renal cell carcinoma 
and correlates with the down-regulation of protein tyrosine 
phosphatase receptor delta. Cancer. 2011; 117:4201–4211.
12. Schraml P, Struckmann K, Bednar R, Fu W, Gasser T, 
Wilber K, Kononen J, Sauter G, Mihatsch MJ, Moch H. 
CDKNA2A mutation analysis, protein expression, and 
deletion mapping of chromosome 9p in conventional 
clear-cell renal carcinomas: evidence for a second tumor 
suppressor gene proximal to CDKN2A. The American 
journal of pathology. 2001; 158:593–601.
13. Presti JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, 
Waldman F. Allelic loss on chromosomes 8 and 9 correlates 
with clinical outcome in locally advanced clear cell 
carcinoma of the kidney. The Journal of urology. 2002; 
167:1464–1468.
14. Hu N, Clifford RJ, Yang HH, Wang C, Goldstein AM, 
Ding T, Taylor PR, Lee MP. Genome wide analysis of DNA 
copy number neutral loss of heterozygosity (CNNLOH) and 
its relation to gene expression in esophageal squamous cell 
carcinoma. BMC genomics. 2010; 11:576.
15. Saeki H, Kitao H, Yoshinaga K, Nakanoko T, Kubo N, 
Kakeji Y, Morita M, Maehara Y. Copy-neutral loss of 
heterozygosity at the p53 locus in carcinogenesis of 
esophageal squamous cell carcinomas associated with p53 
mutations. Clinical cancer research. 2011; 17:1731–1740.
16. El-Mokadem I, Lim A, Kidd T, Garret K, Pratt N, 
Batty D, Fleming S, Nabi G. Microsatellite alteration and 
immunohistochemical expression profile of chromosome 
9p21 in patients with sporadic renal cell carcinoma 
following surgical resection. BMC cancer. 2016; 16:546.
17. Ficarra V, Novara G, Galfano A, Brunelli M, Cavalleri S, 
Martignoni G, Artibani W. The Stage, Size, Grade and 
Necrosis' score is more accurate than the University of 
California Los Angeles Integrated Staging System for 
predicting cancer-specific survival in patients with clear cell 
renal cell carcinoma. BJU international. 2009; 103:165–170.
18. Sobin L GM, Wittekind C. TNM classification of malignant 
tumors. UICC International Union Against Cancer. In. 
Edited by UICC, 7 edn. USA: Wiley-Blackwel; 2009.
19. Ficarra V, Martignoni G, Lohse C, Novara G, Pea M, 
Cavalleri S, Artibani W. External validation of the Mayo 
Clinic Stage, Size, Grade and Necrosis (SSIGN) score to 
predict cancer specific survival using a European series of 
conventional renal cell carcinoma. The Journal of urology. 
2006; 175:1235–1239.
20. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, 
Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of 
progression after radical nephrectomy for patients with clear 
cell renal cell carcinoma: a stratification tool for prospective 
clinical trials. Cancer. 2003; 97:1663–1671.
21. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, 
Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, 
Suzuki H, et al. Integrated molecular analysis of clear-cell 
renal cell carcinoma. Nature genetics. 2013; 45:860–867.
22. Toma MI, Grosser M, Herr A, Aust DE, Meye A, 
Hoefling C, Fuessel S, Wuttig D, Wirth MP, Baretton GB. 
Loss of heterozygosity and copy number abnormality in 
clear cell renal cell carcinoma discovered by high-density 
affymetrix 10K single nucleotide polymorphism mapping 
array. Neoplasia. 2008; 10:634–642.
23. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, 
Kawamata N, Hangaishi A, Kurokawa M, Chiba S, 
Gilliland DG, et al. Highly sensitive method for 
genomewide detection of allelic composition in nonpaired, 
primary tumor specimens by use of affymetrix single-
nucleotide-polymorphism genotyping microarrays. 
American journal of human genetics. 2007; 81:114–126.
24. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, 
Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, 
et al. Genomic architecture and evolution of clear cell renal 
cell carcinomas defined by multiregion sequencing. Nature 
genetics. 2014; 46:225–233.
